Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BLSM | PRESS-RELEASE | bullish | 6/10 | BlossomHill Therapeutics priced its upsized IPO of 9,375,000 shares at $16.00/share, raising $150.0 million in gross pro | Aug 6, 2026 |
| LTGO | PRESS-RELEASE | neutral | 4/10 | Latigo Biotherapeutics priced its upsized IPO of 19,200,000 shares at $18.00 per share, raising $345.6 million in gross | Aug 6, 2026 |
| CMND | 6-K | bullish | 5/10 | Clearmind Medicine announced that its independent DSMB unanimously cleared progression to Parts B and C of the Phase I/I | Aug 6, 2026 |
| PBM | 6-K | neutral | 4/10 | Psyence Biomedical filed an August 2026 investor presentation via Form 6-K. The presentation is a routine corporate upda | Aug 6, 2026 |
| DNLI | 8-K | mixed | 6/10 | Denali Therapeutics reported Q2 2026 results with AVLAYAH generating $3.6M in its first full commercial quarter, beating | Aug 6, 2026 |
| APUS | 8-K | neutral | 2/10 | Apimeds Pharmaceuticals appointed Dr. Christopher Kim as Chief Scientific Officer, effective August 5, 2026, to lead the | Aug 6, 2026 |
| TNGX | 8-K | neutral | 2/10 | Tango Therapeutics disclosed the end of Dr. Barbara Weber's employment as Executive Chair, effective August 3, 2026, wit | Aug 6, 2026 |
| IOVA | 8-K | neutral | 3/10 | Iovance Biotherapeutics filed an 8-K with an updated corporate presentation used at healthcare conferences. The presenta | Aug 6, 2026 |
| PLSE | 8-K | bearish | 5/10 | Pulse Biosciences entered into an equity distribution agreement with Mizuho Securities to sell up to $75 million of comm | Aug 6, 2026 |
| CORT | CLUSTER | neutral | 2/10 | Three executives at Corcept Therapeutics sold a combined $3.88M in open-market stock over a 7-day window, including the | Aug 6, 2026 |
| BIIB | PRESS-RELEASE | neutral | 4/10 | Biogen acquired RayThera Inc., a private immunology biotech, adding a Phase 1 small-molecule program and pipeline assets | Aug 6, 2026 |
| GILD | S-3ASR | neutral | 2/10 | Gilead Sciences filed an automatic shelf registration statement (S-3ASR) on August 6, 2026, registering an indeterminate | Aug 6, 2026 |
| PLSE | 424B5 | bearish | 5/10 | Pulse Biosciences filed a 424B5 prospectus supplement for an at-the-market (ATM) offering of up to $75 million of common | Aug 6, 2026 |
| CLLS | PRESS-RELEASE | mixed | 5/10 | Cellectis reported Q2 2026 EPS of -$0.18, beating consensus of -$0.26 by 31.6%, but revenue of $5.2M missed estimates of | Aug 6, 2026 |
| PRPH | 8-K | bearish | 7/10 | ProPhase Labs entered into a senior secured convertible loan agreement with J.J. Astor & Co. for $1.5 million, which car | Aug 6, 2026 |
| SLDB | S-3ASR | neutral | 4/10 | Solid Biosciences filed an S-3ASR shelf registration statement, registering an unlimited amount of senior and subordinat | Aug 6, 2026 |
| ALT | INST-CLUSTER | neutral | 5/10 | No summary provided | Aug 6, 2026 |
| INKT | PRESS-RELEASE | bullish | 6/10 | MiNK Therapeutics presented initial Phase 2 data at MHSRS showing first patients treated with agenT-797 for severe hypox | Aug 6, 2026 |
| ASND | 6-K | bullish | 7/10 | Ascendis Pharma provided a comprehensive update on its achondroplasia programs, including Week 78 data from the COACH co | Aug 6, 2026 |
| NRSN | 6-K | bullish | 6/10 | NeuroSense announced completion of the Pre-NDS process with Health Canada for PrimeC in ALS, with alignment on submissio | Aug 6, 2026 |
| GMAB | 6-K | bullish | 6/10 | Genmab reported strong H1 2026 results with revenue up 25% YoY to $2,051M, driven by DARZALEX and Kesimpta royalties and | Aug 6, 2026 |
| GPRE | 8-K | mixed | 5/10 | Green Plains reported Q2 2026 net income of $67.1M ($0.83 diluted EPS) versus a net loss of $72.2M in Q2 2025, driven by | Aug 6, 2026 |
| TLSA | 6-K | bullish | 5/10 | Tiziana Life Sciences CEO Ivor Elrifi purchased 321,423 common shares at $1.00 per share on the open market, increasing | Aug 6, 2026 |
| INSM | 8-K | bullish | 8/10 | Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estimates of $393.4M, driven by a 49% sequential surge in | Aug 6, 2026 |
| AVTX | 8-K | bullish | 6/10 | Avalo Therapeutics reported Q2 2026 results with a net loss of $36.4M ($0.83/share), missing consensus of $0.66. The com | Aug 6, 2026 |
| FHTX | 8-K | mixed | 5/10 | Foghorn Therapeutics reported Q2 2026 financial results with a net loss of $7.2M, significantly narrower than the $17.9M | Aug 6, 2026 |
| IMCR | 8-K | mixed | 5/10 | Immunocore reported Q2 2026 KIMMTRAK revenue of $115.9M (+18% YoY), beating consensus of $110.4M, but posted a small net | Aug 6, 2026 |
| AMLX | 8-K | neutral | 5/10 | Amylyx Pharmaceuticals reported Q2 2026 financial results with a net loss of $43.4M ($0.39/share), missing the consensus | Aug 6, 2026 |
| VRDN | 8-K | bullish | 7/10 | Viridian Therapeutics reported Q2 2026 results highlighting the FDA approval and U.S. launch of Lumvoa (veligrotug-vvze) | Aug 6, 2026 |
| IOVA | 8-K | bullish | 7/10 | Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi revenue of ~$91M. Gross m | Aug 6, 2026 |